July 10, 2015

Announcements

Clinical Trial Accrual Reaches New High
With the conclusion of our fiscal year last week, I am very pleased to report that our total therapeutic patient accrual to clinical trials was 846. This exceeded our projected goal of 715 by more than 18%. The clinical research culture that we have created at Yale Cancer Center and Smilow Cancer Hospital over the past few years has brought new clinical advances to our patients, and extended the availability of new treatment options to patients worldwide.

Thank you to every one of you who participated in this amazing team effort, from our regulatory group, to our CRAs, CRCs, Lead CRCs, APRNs, nurses, and physicians. I would also like to extend my appreciation to Dr. Howard Hochster, Associate Director for Clinical Sciences, Dr. Patricia LoRusso, Associate Director for Innovation, and Rhoda Arzoomanian, Director of our Clinical Trials Office for their leadership and vision.

Over the last year we had 78 physicians caring for patients on clinical trials; more than 500 patients on clinical trials at any one time; nearly 1,000 patients in follow-up care at any point; and more than 150 trials open to accrual!

This is a fantastic increase from the 540 patients accrued during the previous 12 months and I look forward to continued success in fiscal year 2016 with even larger growth at Smilow Cancer Hospital, in our Care Centers, and on the Saint Francis campus in Hartford.

Research in the News
Yale Team Finds why BRCA Gene Resists Cancer Treatment

Yale University researchers have discovered why a key molecular assistant is crucial to the function of the BRCA2 gene, which in some mutant forms can lead to ovarian and breast cancer in as many as 6 in 10 women.

The findings suggest how biochemists might be able to decrease drug resistance to existing therapies that target this form of cancer, the authors reported their findings in the July 2 issue of the journal *Molecular Cell*.

"We can design specific targets for drug development only if we fully understand the key players and how they work in the pathway for repairing DNA breaks," said Patrick Sung, professor in the Department of Molecular Biophysics and Biochemistry, researcher at Yale Cancer Center, and senior author of the paper.

Employee Profile: Phil Kearney

Phil Kearney is Studio Operations Manager at the Yale Broadcast Center, which provides a wide range of video and audio services to the Yale community. In Phil's role, he works closely with Yale Cancer Center staff to tape Yale Cancer Center Answers, a weekly radio program on WNPR focused on cancer screening, detection, treatment, and prevention. Entering its 10th year on air, Phil has provided consistent and exemplary support for much of that time.

Phil also assists with live broadcasts for Yale Cancer Center and Yale School of Medicine faculty to appear on networks such as CNN, BBC, NBC, CNBC, MSNBC, ABC and CBS. In addition, he produces content for and administers the Yale iTunesU podcast collections. The Yale Broadcast Center includes two fully-equipped television studios, an audio recording studio, and editing suites. The mission of the Center is to support Yale faculty members, researchers, administrators, and other community members by providing media support to facilitate participation in the global media dialog on issues of societal importance. As
part of the newly formed Center for Teaching and Learning, YBC provides production support for Yale online courses.

Phil commented that working with Yale Cancer Center staff has been a rewarding experience. "As with so many people I know, my own family has been touched by cancer. Both my father and brother are cancer survivors. Being able to participate in providing the greater community with information about cancer treatment options and personal stories of survivorship has been gratifying," said Phil.

Working with the hosts of Yale Cancer Center Answers, Dr. Anees Chagpar, Dr. Steven Gore, and Dr. Susan Higgins, and their guests, Phil is able to make sure everything runs smoothly, including time and sound quality. He has been in the broadcast industry for 18 years and started his career with NBC30 Hartford in news production. Phil has been at Yale for the past 15 years.

"Our department has been working with the Yale Broadcast Center and Phil for many years. Phil has always been a constant in making Yale Cancer Center Answers a success. He is accommodating when it comes to scheduling, and his friendly demeanor puts guests at ease," said Emily Fenton, Marketing Coordinator in Public Affairs and Marketing at Yale Cancer Center. "We are lucky to have such a professional and experienced person working with us behind the scenes."

### Funding and Award Opportunities

**NCCN Pfizer Metastatic Breast Cancer Request for Proposals**

National Comprehensive Cancer Network® (NCCN®) is pleased to announce it is collaborating with Pfizer’s Independent Grants for Learning & Change (IGLC) team to offer a grant opportunity focused on improving care for patients with metastatic breast cancer, where treatment goals focus on improving quality and length of life as there is, to date, no known cure.

**Letter of Intent Deadline:** July 15, 2015

[Learn More >>](#)

**AACR-Genentech BioOncology Career Development Award for Cancer Research on the HER Family Pathway**

The AACR-Genentech BioOncology Career Development Award for Cancer Research on the HER Family Pathway represents a joint effort to encourage and support a

[New research from Yale discovers why the BRCA gene resists treatment.](#)

[Read More >>](#)

Smilow Cancer Hospital has partnered with [Saint Francis Hospital](#) to give Saint Francis patients enhanced access to
physician-scientist to conduct cancer research on the HER Family Pathway and to establish a successful career path in this field. Eligibility is limited to junior faculty-level physician-scientists who, at the start of the grant term, will have completed their most recent medical residency or doctoral degree within the past 11 years.

**Application Deadline:** July 22, 2015

**Learn More >>**

**YCCI Scholar Awards**

YCCI Scholar Awards provide salary and/or research funds to a select number of junior faculty members who are strongly committed to careers in clinical research, community-based research or translational research. Individuals must be nominated by a department chair/division head/section chief, or center/program director. The primary aim of these awards are to prepare the applicant for successful independent research careers, and emphasis will be placed on career development and mentoring plans.

**Application Deadline:** July 24, 2015

**Learn More >>**

**Faculty Scholars Competition**

The Simons Foundation, Howard Hughes Medical Institute (HHMI) and the Bill & Melinda Gates Foundation are pleased to announce the Faculty Scholars Competition, a national competition for grants to outstanding early-career scientists.

The three philanthropies will award a total of $148 million over the program's first five years, awarding up to 70 grants every two and a half to three years. The awards are intended for basic researchers and physician scientists who have already demonstrated significant research accomplishments and show potential to make unique and important contributions to their fields.

The Faculty Scholars Competition marks the first time that HHMI, the Bill & Melinda Gates Foundation and the Simons Foundation have formally undertaken an initiative together.

**Application Deadline:** July 28, 2015

**Learn More >>**

**AACR NextGen Grants for Transformative Cancer Research**

These three-year grants of $450,000 represent a new AACR funding initiative to stimulate highly innovative research from young investigators. Eligibility is limited to junior faculty who have held a full-time, tenure-track
appointment as an assistant professor for no more than three years.

**Letter of Intent Deadline:** August 10, 2015

**Learn More >>**

### Patterson Trust Fellowship Program in Clinical Research

The Robert E. Leet and Clara Guthrie Patterson Trust was established in 1980 for the advancement of medical science, particularly research "relating to human diseases, their causes and relief." Two-year fellowships of $90,000 ($45,000 per year) will be awarded to Applicants working in Connecticut or New Jersey.

The Patterson Trust will provide support to early-stage mentored investigators conducting clinical research with a focus on patient-oriented or translational laboratory research. The Program will help the Trust to pursue its mission by providing Applicants with the opportunity to demonstrate creativity and explore opportunities that may promote careers in clinical research. Pilot and preliminary studies are encouraged.

**Application Deadline:** August 14, 2015

**Learn More >>**

### 2015 Rausch Pilot Research Grant

To provide seed money to members of Yale Cancer Center (YCC) to enable investigators to engage in innovative cancer research, with the goal of facilitating new research on the fundamental causes of, or an effective cure for, cancer. We anticipate funding two to three pilot grants. Priorities for the pilot grants include studying and/or ameliorating sociodemographic disparities in cancer incidence or outcomes; the prevention and/or treatment of women's cancers, as well as neighborhood/urban or other community factors that contribute to cancer etiology. Preference will be given to research that has a high likelihood of having a demonstrable community impact in the Greater New Haven area.

**Application Deadline:** August 14, 2015

**Learn More >>**

### Provocative Questions in Cancer with an Underlying HIV Infection (R01)

The purpose of this funding opportunity announcement (FOA) is to advance our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS) through research directed at addressing one of several proposed “Provocative Questions” (PQs). These PQs are

**Personalized Medicine**


**Here's a peek at what goes on at academic #cancer centers like ours:** [http://bit.ly/1HOs5kA](http://bit.ly/1HOs5kA) @YaleMed @YNHH @InsideYCC

**Dr. Patrick Sung and team find new protein that may thwart drug resistance in #cancer treatment** [http://bit.ly/1IJr66f](http://bit.ly/1IJr66f)

**Bring Back Prostate Screening** [http://nyti.ms/1JIOMZU](http://nyti.ms/1JIOMZU)

**We're making progress! - Indoor Tanning Rates Decline As Cancer Warnings Mount** [http://t.usnews.com/Zaydxc](http://t.usnews.com/Zaydxc) via @usnews

**Yale breast cancer study uses texting to continue treatment** [http://wp.me/p4ySuM-ztt](http://wp.me/p4ySuM-ztt) via @WTNH

**Dr. Howard S. Hochster on TAS-102 Compared to 5FU** [https://shar.es/1q8PLG](https://shar.es/1q8PLG) via @OncLive

**Listen to @DeVitaDoctor discuss the future of #cancer research in the latest JNCI podcast.**

**Closer to Free**

[The fund to advance cancer research and enhance patient care](http://closerfree.org)

**Events**
not intended to represent the full range of NCI's priorities in HIV/AIDS-related cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific problems and paradoxes in key areas of AIDS-related cancer research that are deemed important but have not received sufficient attention.

**Application Deadline**: August 18, 2015

Learn More >>

### Class of '61 Yale Cancer Research Award

In order to recognize significant accomplishment and continuing outstanding promise in cancer research, Yale Cancer Center is pleased to announce the Class of '61 Yale Cancer Research Award. This annual award recognizes significant accomplishment in cancer research at Yale University by a young member of the faculty, coupled with the expectation for future outstanding contributions to our understanding of the causes and cures for cancer. The annual award, established through the ongoing generosity of the Yale College Class of 1961, will provide unrestricted funds to support the winner's cancer research. The initial award will be $50,000. Nominees must be Yale faculty members age 45 or less, whose accomplishments are documented by published papers and awarded grants in any area of cancer research including seminal investigations into basic cancer biology, important translational or clinical studies, or critical population science studies.

**Nomination Deadline**: August 31, 2015

Learn More >>

### Assay Validation For High Quality Markers For NCI-Supported Clinical Trials

The purpose of this Funding Opportunity Announcement (FOA) is to improve the development and validation of molecular diagnostics for the treatment, control, or prevention of cancer. This FOA includes, but is not limited to, the validation of prognostic, predictive or response markers for treatment and markers for cancer control or prevention trials. Applicants should have an assay that works in human samples and whose importance is well justified for development into a clinical assay. In addition, analytical validation of assays for these markers should be achieved when the application is submitted so that clinical validation may be achieved with little further analytical validation needed. This supplement may be used to support acquisition of specimens from retrospective or prospective studies from NCI-supported or other clinical trials. Clinical laboratory staff, technical and other needs must be an integral part of the application. Assays proposed for this FOA may be used to validate existing assays for use in other cancer clinical trials, observational studies or...
Smoking Cessation within the Context of Lung Cancer Screening

The goal of this Funding Opportunity Announcement (FOA) is to improve the effectiveness and/or implementation of smoking cessation interventions delivered to current smokers who undergo low-dose computed tomography (LDCT) lung cancer screening. The proposed projects must be aimed at determining:

a) the key components and characteristics of an effective smoking cessation intervention delivered in the LDCT setting; and/or

b) characteristics of an implementation strategy to optimally incorporate existing evidence-based smoking cessation intervention(s) into the LDCT setting.

**Application Deadline:** October 8, 2015

Learn More >>

Recent Publications

**AIP1 expression in tumor niche suppresses tumor progression and metastasis.**
Ji W, Li Y, He Y, Yin M, Zhou HJ, Boggon TJ, Zhang H, Min W.
Cancer Res. 2015 Jul 2.
Read More >>

**Reply to: Obesity is an important health problem in survivors of pediatric acute lymphoblastic leukemia.**
Lindemulder SJ, Stork LC, Lu X, Hunger S, Neglia JP, Kadan-Lottick NS.
Read More >>

**Reproducibility of Variant Calls in Replicate Next Generation Sequencing Experiments.**
Read More >>
AGA Clinical Practice Guidelines: Robust, Evidence-Based Tools for Guiding Clinical Care Decisions.
Siedler MR, Allen JI, Falck-Ytter YT, Weinberg DS.
Gastroenterology. 2015 Jun 29.
Read More >>

The Affordable Care Act and Expanded Insurance Eligibility Among Nonelderly Adult Cancer Survivors.
Davidoff AJ, Hill SC, Bernard D, Yabroff KR.
J Natl Cancer Inst. 2015 Jul 1;107(9).
Read More >>

The Role of Patient Factors, Cancer Characteristics, and Treatment Patterns in the Cost of Care for Medicare Beneficiaries with Breast Cancer.
Health Serv Res. 2015 Jun 29.
Read More >>

YU238259 is a Novel Inhibitor of Homology-dependent DNA Repair that Exhibits Synthetic Lethality and Radiosensitization in Repair-deficient Tumors.
Read More >>

Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.
Kon Kim T, Gore SD, Zeidan AM.
Read More >>

Intravital imaging of hair follicle regeneration in the mouse.
Pineda CM, Park S, Mesa KR, Wolfel M, Gonzalez DG, Haberman AM, Rompolas P, Greco V.
Read More >>

Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer.
J Clin Oncol. 2015 Jun 22.
Read More >>

Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
Iyer SP, Foss FF.